The decision of adjuvant therapeutic modalities is taken according to several prognostic and/or predictive factors including patient age, tumor size, histological type and grade, lymph node involvement and expression on the tumor of hormone receptors for estrogen (ER) progesterone (PR), and the human epidermal growth factor receptor 2 (HER2) as well as the percentage of tumor cells expressing the nuclear proliferation marker Ki672. Here, NR4A1 is linked to neoplasm.